Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases: Volume 2

Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases: Volume 2

Paperback(Softcover reprint of the original 1st ed. 1990)

Choose Expedited Shipping at checkout for guaranteed delivery by Friday, April 26

Product Details

ISBN-13: 9781468458497
Publisher: Springer US
Publication date: 08/01/2012
Series: Advances in Behavioral Biology
Edition description: Softcover reprint of the original 1st ed. 1990
Pages: 638
Product dimensions: 7.01(w) x 10.00(h) x 0.05(d)

Table of Contents

Marker.- Modifications of Neuroendocrine Function during Alzheimer Type Dementia.- Preparation of Monoclonal Antibody against a Beta Protein Subpeptide and Screening for Immunoreactivity in the Sera of Patients with Alzheimer’s Disease.- Study on Vitamin B12 Levels in Serum and Cerebrospinal Fluid of Patients with Alzheimer’s Disease.- Serum and Cerebrospinal Fluid Vitamin B12 Levels in Demented Patients Treated with CH3-B12.- Neurochemical Markers in the Cerebrospinal Fluid of Patients with Alzheimer-Type Dementia.- The Value of Cholinergic Receptors in Blood Lymphocytes Measured by (3H)Quinuclidinyl Benzilate (3H)QNB for the Diagnosis of Cholinergic Related Dementia.- Reduced Natural Killer Cell Activity in Dementia of the Alzheimer Type.- CSF of Patients with Alzheimer’s Disease Contain Antibodies Recognizing Cholinergic Cells in the Rat CNS, and Can Protect Cholinergic Neuronal Cultures.- Alterations of Transferrin and Prealbumin in Cerebrospinal Fluid in Parkinson’s Disease.- Clinical Investigation of Neurotransmitters in Extrapyramidal System Diseases.- Total Biopterin and Neopterin Levels in the Ventricular CSF of Patients with Parkinson’s Disease.- Manganese Content in Hair of Patients with Parkinson’s Disease: Manganese Deficiency and Susceptibility towards Parkinson’s Disease.- Imaging.- Single Photon Emission Computed Tomography in Alzheimer-Type Dementia.- Application of Magnetic Resonance Imaging to a Primate Model of the Cholinergic Deficit of Alzheimer’s Disease.- In Vivo Phosphorous-31 NMR Spectroscopy in Alzheimer’s Disease.- White Matter Abnormalities on MRI in Probable Alzheimer’s Disease.- Progressive Aphasia without Global Dementia Examined by Dynamic PET Scan.- Positron Emission Tomography Studies Using 11C-Labelled Dopa and Effect of Tetrahydrobiopterin on Dopamine Release.- Striatal Presynaptic Dopaminergic Function and Cerebral Blood Flow in the MPTP Primate Model of Parkinson’s Disease by PET.- Cerebral Blood Flow (CBF) Pattern in Progressive Supranuclear Palsy and Clinico-CBF-MRI Correlations.- Nuclear Resonance Imaging in Parkinsonism Analytical Study of “Pars Compacta”.- Magnetic Resonance Imaging of Parkinson’s Disease.- Comparison of Local Cerebral Glucose and Dopamine Metabolism between Parkinson’s Disease and Parkinsonism by Positron Emission Tomography.- Striatal Dopamine D2 Receptors in Parkinson’s Disease and StriatoNigral Degeneration Determined by Positron Emission Tomography.- Clinical Aspect-1 (Alzheimer).- Alzheimer Type Dementia — One or Several Disorders ?.- Quantitative Topographic Analysis of EEG in Alzheimer’s Disease.- The Concept of Subcortical Dementia (SCD): Are There Clinical Anatomical, Biochemical and Neurophysiological Basis ?.- Vascular Dementia (VD) and Primary Degenerative Dementia (PDD): Criteria for Differential Diagnosis.- Cognitive Functions in Senile Dementia of the Alzheimer Type: Interaction in the Cognitive Measures.- Is It Useful to Manage Alzheimer’s Disease as Two Clinical Subtypes: Early Onset and Late Onset Subtypes ?.- A Memory Clinic Located in a General Hospital: First Results.- Visual Cognitive Disturbance in Alzheimer’s Disease — A Study by Means of Vision Analyzer as a New Method for Eye Movement.- Electrophysiological Comparison between Parkinson’s Disease and Alzheimer’s Disease.- A Clinical EEG Study of Alzheimer-Type Dementia.- A Case of Alzheimerism Induced by Trihexyphenidyl.- Probable Alzheimer’s Disease with Appearance of Periodic Synchronous Discharges for a Long Period.- Incidence and Prevalence of Alzheimer-Type Dementia: Epidemiological Investigations in 1987, 1988, and 1989.- Differences in Memory Impairment in Patients with Alzheimer’s Disease and Parkinson’s Disease with and without Dementia.- Clinical Aspect-2 (Parkinson).- Dementia in Parkinson’s Disease.- Juvenile or Early-Starting Parkinsonism as a Prototype of Nigrostriatal Dopamine Deficiency.- Clinical Features of Autòsomal Recessive Type Juvenile Parkinsonism and Improvement of Symptoms by Smoking.- The Prognostic Comparison between the Progressive Clinical Course and the Stable Course of Parkinson’s Disease Over 10 Years.- Familial Parkinson’s Disease and Familial Manic-Depressive Illness.- Neuropsychological Disturbances in Parkinson’s Disease.- Study on Incidence of Cancer and Smoking Rate in Parkinson’s Disease.- High Speed Memory Scanning in Parkinson’s Disease: Adverse Effect of L-Dopa.- Wechsler Adult Intelligence Scale and Other Related Factors for Parkinson’s Disease Patients, Main Focus: Brain Function.- Study on Relationship between Computed Tomography Brain Changes and Motor Function in Parkinson’s Disease.- A Patient Presenting Mainly Dystonia in a Family with Juvenile Parkinsonism.- Hereditary Dystonia-Parkinsonism Syndrome of Juvenile Onset with Marked Diurnal Fluctuations.- Dystonia-Parkinsonism Syndrome Showing Good Response to an AntiCholinergic Drug but Not to L-DOPA.- Neuroleptic Malignant Syndrome Associated with Withdrawal of Antiparkinsonian Drugs.- Freezing of Gait and Resistance to Dopaminergic Therapy.- Normal Thyroid Function in 50 Patients with Parkinson’s Disease.- Risk Factors to Parkinson’s Disease; Heritability and Life Styles.- Prevalence of Parkinson’s Disease in Izumo City, Japan.- Clustering of Parkinson’s Disease in Southern Israel An Endemic Parkinsonism-Impaired Vibration Sense Syndrome.- The Exteroceptive Control of Voluntary Muscle Contraction in Parkinsonism.- Exteroceptive Suppression of the Masseter and Temporalis Muscles in Patients with Parkinson’s Disease.- Mechanism of the Difficulty in Set Shifting Task in Parkinson’s Disease.- Cerebral Blood Flow, Evoked Potential and Reaction Time in Parkinson’s Disease.- Topography of Auditory Event-Related Potentials in Parkinson’s Disease.- Sleep-Wake Complaints in Parkinson’s Disease.- Estimation of Biopterin and Neopterin in Cerebrospinal Fluid in Parkinson’s Disease.- Quantitative Evaluation of Vocal Changes in Parkinson’s Disease: Intercorrelation among Voice Parameters and Monoamine Systems.- Periodic Movements During Sleep in Patients with Parkinson’s Disease.- Therapy-1(Alzheimer).- (+)-CIS-Methyl-Spiro(1,3-Oxathiolane-5,3’)Quinuclidine (AF102B): A New M1 Agonist as a Rational Treatment Strategy in Alzheimer’s Disease — An Overview.- Behavioral and Neurochemical Effects of AF64A in Young and Old Fischer 344 Male Rats.- Selection of Cholinergic Agents Which May Improve Memory.- Rationale for the Planned Clinical Trials with Nerve Growth Factor in Alzheimer’s Disease.- Neurochemical and Psychopharmacological Assessment of the M1-Selective Agonist AF102B (FKS-508).- Effects of Acute and Chronic Administration of the New Muscarinic Agonist SDZ BOP-086 on Phosphoinositide Hydrolysis.- Evaluation of “Nootropic” Drug in Rats by the Radial Maze Task: Problem of Order in Administering Scopolamine and Testing Drug and Effect of a Specific Cholinergic Agonist, SDZ-210-086.- Effect of DM-9384, a New Pyrrolidone Derivative, on Passive Avoidance and Cerebral Choline Acetyltransferase Activity in Rats.- DM-9384, a Pyrrolidone Derivative, Ameliorates Basal Forebrain Lesion-Induced Amnesia and Inhibits Cycloheximide-Induced Decrease in the Number of GABA and Acetylcholine Receptors.- The Effect of Chinese Herbal Medicine TJ-23 (Toki-Syakuyaku-San) on the Choline Acetyltransferase Activity in the Cortex of Rat.- Effect of TJ-23 on Scopolamine-Induced Deficit of Learning and Memory in Rats.- Advantages of a Visual Recognition Task to Detect Cognitive Facilitation by Cholinomimetic Drugs in Primates.- Tetrahydroaminoacridine and Some of Its Analogues: Effects on the Cholinergic System.- Pharmacological Studies of Cerebroactive Drugs.- Effects of Tetrahydroaminoacridine on Passive Avoidance and Endogenous Nerve Growth Factor Levels in Rats.- SM-10888, a New Drug Candidate for Treatment of Senile Dementia of the Alzheimer Type.- Inhibitory Action of E2020, a Novel Acetylcholinesterase Inhibitor, on Cholinesterase: Comparison with Other Inhibitors.- Inhibitory Action of Nicergoline and Its Major Metabolites on Acetylcholinesterase Activity in Rat and Mouse Brain.- Changes in Discrimination Learning Ability in Rats with Ibotenic Acid-Induced Lesions in the Nucleus Basalis Magnocellularis..- SDZ ENA 713, an Acetylcholinesterase-Inhibitor with Preference for Central Activity: Animal Studies.- Development of a Cognitive Drug with the Ability to Modulate Glutamate (Glu) and Aspartate (Asp).- Nerve Growth Factor and Staurosporine Facilitate Recovery from Basal Forebrain Lesion-Induced Amnesia in Rats.- Effects of Nootropic Drugs on Experimentally Induced Amnesia of Rats in the Three-Panel Runway Task.- Effects of KW-6055, a Novel Benzylpyridine Derivative, on Brain Monoaminergic Systems of Rats.- Effects of KW-6055, a Novel Benzylpyridine Derivative, on Various Experimental Amnesia Models.- Vasopressin Fragments Improve Learning Process of Rats in the Radial Arm Maze Task.- Evaluation of Vasopressin Fragments and Their Analogues on Active Avoidance Responses of Rats with Lesions of the Dorsal Norepinephrine Bundle.- Anti-Amnestic and Anti-Anoxic Effects of Droxidopa (L-DOPS) in Animal Models.- Amelioration of Delayed Neuronal Death of the Hippocampus by Nerve Growth Factor.- Long-Term Actions of Nicotinic Receptor Stimulation in Nucleus Basalis Lesioned Rats: Blockade of Trans-Synaptic Cell Loss.- Measuring Efficacy of Reversible Cholinesterase Inhibitors for Alzheimer’s.- Quantitative Pharmaco-Electroencephalographic Study on Acetyl-LCarnitine in Geriatric Patients with Dementia.- Megavitamin Therapy (Coenzyme Q10 and Vitamin B6) in Alzheimer’s Disease and Senile Dementia of Alzheimer Type.- Therapy-2(Parkinson).- Assessment of Novel Sustained Release Antiparkinsonian Therapies in MPTP-Treated Primates.- Behavioral Effects of Dopamine-Agonists on MPTP-Induced Parkinsonism in Cynomolgus Monkeys.- Effect of Basic Fibroblast Growth Factor on Midbrain and Other CNS Neurons in Primary Culture Derived from Postnatal and Fetal Rat Brain.- Towards a Strategy for Preventing Parkinson’s Disease.- Tetrahydrobiopterin Therapy for Juvenile Parkinsonism.- Application of a Low-Protein Diet for Parkinson’s Disease.- apy for Freezing of Parkinson’s Disease.- Pharmacokinetic and Pharmacodynamic Studies with Controlled-Release Carbidopa/Levodopa.- Results of a Multicentre Study Comparing the Effects of a Controlled Release Preparation (Madopar CR) with Conventional Levodopa.- An Open Study of Evening Doses of Slow-Release L-Dopa (Madopar HBS) in Parkinson Patients with Nocturnal Disabilities.- To the Principles of Levodopa Therapy Including Slow Release Form..- A New Prodrug of L-DOPA to Attain Prolonged Plasma Concentration.- French Open Clinical Study of Modopar LP (HBS) in Parkinsonians.- Four Years of Experience in the Treatment of Parkinsonian Patients with a Controlled-Release Levodopa (HBS).- Antiparkinsonian Effects of Lisuride and Binding of the Drug to D-2 and 5-HT1A Receptors in Cynomolgus Monkeys.- Treatment of Motor Fluctuations in Parkinson’s Disease with Subcutaneous Apomorphine.- Lisuride and Proterguride Reverse MPTP-Induced Parkinsonism in the Common Marmoset.- Terguride, a Dopamine Partial Agonist for the Treatment of Parkinson’s Disease.- The Beneficial Effect of Lisuride Hydrogen Maleate in the Long Term Treatment of Parkinson’s Disease.- Selegiline in the Treatment of Daily Fluctuations in Disability — A Double-Blind Study.- Pharmacological Activity of a Novel Dopamine D2 Agonist (SK&F 101468) in Man.- SK&F 101468, a Novel Dopamine D2 Agonist in Parkinson’s Disease...- Pharmacological Evaluation of SK&F 101468-A, in MPTP Treated Marmosets.- SK&F 101468-A, a Possible Drug for the Treatment of Parkinson’s Disease.- General Discussion.

Customer Reviews

Most Helpful Customer Reviews

See All Customer Reviews